Japanese Ministry Of Health Approves Novartis’ Rasilez
For the treatment of high blood pressure alone or in combination with other high blood pressure medicines
Novartis has received the approval for Rasilez (aliskiren), a high blood pressure medicine, for use in Japan. Rasilez directly inhibits renin, an enzyme that triggers a process leading to high blood pressure and organ damage.
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Rasilez for the treatment of high blood pressure, alone or in combination with other high blood pressure medicines.
The potential long-term benefits of Rasilez are currently being investigated further in the ASPIRE HIGHER program, involving more than 35,000 patients in 14 trials.
Trevor Mundel, Global Head of Development at Novartis, said: We are very excited about the approval in Japan, which provides Japanese patients access to this innovative high blood pressure treatment that directly targets rennin.
Rasilez is approved in over 70 countries. Tekturna was approved in the US in March 2007 and in the European Union in August 2007, under the trade name - Rasilez.
Related Insight
Suppliers Directory
Crossject - Needle-Free Device Technology
Crossject is a leader in the design and development of innovative needle-free device technology for the pharmaceutical industry.
Suppliers
World Courier - Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry
For over 40 years, World Courier has set the standard for worldwide time- and temperature-sensitive transportation services to the pharmaceutical industry. World Courier works with customers to ensure regulatory compliance and supply chain integrity, and to identify and deliver the best logistical solutions for each individual study or consignment.
Suppliers
BioCis Pharma - ProtoDynamic Therapy Technology
BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform.
Suppliers
Haselmeier - Self-Injection Devices
Haselmeier is dedicated to meeting the self-injection needs of pharmaceutical manufacturers and patients.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
A New Approach to Outsourced Drug Development
Published by INC Research
White Papers
SAS® Drug Development
Published by Celerion
White Papers
EDMS Based QA/QC Documentation: the Lasting Answer to GxP Challenges
Published by Infotehna Group
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.